|
US5591855A
(en)
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
DE69839338T2
(de)
|
1997-02-05 |
2008-07-10 |
Warner-Lambert Company Llc |
Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
US20040006074A1
(en)
|
1998-04-28 |
2004-01-08 |
The Government Of The United States Of America |
Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
|
|
CA2335115C
(en)
|
1998-06-16 |
2009-01-27 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Fused azepinone cyclin dependent kinase inhibitors
|
|
DE60037394T2
(de)
|
1999-01-29 |
2009-01-02 |
The Board Of Trustees For The University Of Illinois, Urbana |
VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
|
|
US6958333B1
(en)
|
1999-07-26 |
2005-10-25 |
Banyu Pharmaceutical Co., Ltd. |
Biarylurea derivatives
|
|
US6387900B1
(en)
|
1999-08-12 |
2002-05-14 |
Pharmacia & Upjohn S.P.A. |
3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
|
|
US6291504B1
(en)
|
1999-10-20 |
2001-09-18 |
Dupont Pharmaceuticals Company |
Acylsemicarbazides and their uses
|
|
WO2001044247A2
(en)
|
1999-12-16 |
2001-06-21 |
Eli Lilly And Company |
Agents and methods for the treatment of proliferative diseases
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
PL359563A1
(pl)
|
2000-06-26 |
2004-08-23 |
Pfizer Products Inc. |
Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne
|
|
DK1325011T3
(da)
|
2000-09-29 |
2004-08-16 |
Lilly Co Eli |
Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
|
|
AU2002228692A1
(en)
|
2000-12-01 |
2002-06-11 |
Bristol-Myers Squibb Pharma Company |
3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors
|
|
US6667346B2
(en)
|
2001-02-28 |
2003-12-23 |
Temple University - Of The Commonwealth System Of Higher Education |
Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones
|
|
JP2004533449A
(ja)
*
|
2001-05-11 |
2004-11-04 |
ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム |
Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体
|
|
DE60303009T2
(de)
|
2002-01-22 |
2006-07-13 |
Warner-Lambert Co. Llc |
2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one
|
|
WO2003093469A2
(en)
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
|
JP2006516561A
(ja)
|
2003-01-17 |
2006-07-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
|
|
US7482354B2
(en)
|
2003-05-22 |
2009-01-27 |
Nerviano Medical Sciences S.R.L. |
Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
|
|
JP4053073B2
(ja)
|
2003-07-11 |
2008-02-27 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
選択的ｃｄｋ４阻害剤のイセチオン酸塩
|
|
MXPA06004305A
(es)
|
2003-10-23 |
2006-06-05 |
Hoffmann La Roche |
Derivados de triaza-espiropiperidina para uso como inhibidores del transformador de glicina 1 en tratamiento de enfermedades neurologicas y neuropsiquiatricas.
|
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
|
WO2005094830A1
(en)
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
US8603763B2
(en)
|
2004-04-08 |
2013-12-10 |
Cornell Research Foundation, Inc. |
Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
|
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
|
ES2411975T3
(es)
|
2005-01-14 |
2013-07-09 |
Janssen Pharmaceutica Nv |
Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas
|
|
EP1845975A1
(en)
|
2005-01-21 |
2007-10-24 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors and further antitumor agents
|
|
NZ564065A
(en)
|
2005-05-20 |
2011-03-31 |
Vertex Pharma |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
WO2007025090A2
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
US7579351B2
(en)
|
2005-12-09 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Tricyclic amide derivatives
|
|
BRPI0620151A2
(pt)
|
2005-12-22 |
2010-06-29 |
Wyeth Corp |
composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo
|
|
WO2007124252A2
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
US20070270362A1
(en)
|
2006-05-18 |
2007-11-22 |
The University Of Washington |
Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
|
|
CA2656290A1
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
EP2109450A2
(en)
|
2006-12-14 |
2009-10-21 |
Panacea Pharmaceuticals, Inc. |
Methods of neuroprotection by cyclin-dependent kinase inhibition
|
|
AU2007336933A1
(en)
|
2006-12-22 |
2008-07-03 |
Novartis Ag |
Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
|
|
WO2009003003A2
(en)
|
2007-06-25 |
2008-12-31 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
|
|
WO2009061345A2
(en)
|
2007-11-07 |
2009-05-14 |
Cornell Research Foundation, Inc. |
Targeting cdk4 and cdk6 in cancer therapy
|
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
EP2320903B1
(en)
|
2008-07-29 |
2017-01-18 |
Nerviano Medical Sciences S.r.l. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
|
KR101353857B1
(ko)
*
|
2008-08-22 |
2014-01-21 |
노파르티스 아게 |
Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
|
|
CN102231983A
(zh)
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
|
JP2012504646A
(ja)
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
CA2761896A1
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2011103485A1
(en)
|
2010-02-18 |
2011-08-25 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
MX379532B
(es)
*
|
2010-10-25 |
2025-03-10 |
G1 Therapeutics Inc |
Inhibidores de cdk.
|
|
AU2011323455B2
(en)
|
2010-11-02 |
2017-07-27 |
Promega Corporation |
Coelenterazine derivatives and methods of using same
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
HUE024504T2
(en)
|
2010-12-23 |
2016-01-28 |
Sanofi Sa |
Pyrimidine derivatives, a process for their preparation and their use in medicine
|
|
PT2688887E
(pt)
*
|
2011-03-23 |
2015-07-06 |
Amgen Inc |
Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
|
|
MY161237A
(en)
|
2011-07-01 |
2017-04-14 |
Novartis Ag |
Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
|
|
WO2013148748A1
(en)
|
2012-03-29 |
2013-10-03 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
MY175254A
(en)
|
2012-04-26 |
2020-06-17 |
G1 Therapeutics Inc |
Synthesis of lactams
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
US20140271460A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly Active Anti-Neoplastic and Anti-Proliferative Agents
|
|
US20140274896A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
US9527857B2
(en)
|
2013-03-15 |
2016-12-27 |
GI Therapeutics, Inc. |
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
|
WO2014168975A1
(en)
|
2013-04-08 |
2014-10-16 |
Pharmacyclics, Inc. |
Ibrutinib combination therapy
|
|
US20160257688A1
(en)
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
WO2015084892A1
(en)
|
2013-12-02 |
2015-06-11 |
Cornell University |
Methods for treating b cell proliferative disorders
|
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
US20160220569A1
(en)
|
2015-02-03 |
2016-08-04 |
G1 Therapeutics, Inc. |
CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
|